HC Wainwright keeps Alpha Tau Medical at Buy and lifts target to $18
HC Wainwright maintained its Buy rating on Alpha Tau Medical and raised the price target from $16 to $18, a 12.5% increase.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
HC Wainwright & Co. kept its Buy rating on Alpha Tau Medical shares and raised the price target from $16 to $18, a 12.5% increase. TradingView reports the update, citing data from Benzinga.
According to the source, the new target implies a 99.5% downside from the November 20 close of $3841. That figure looks inconsistent with an $18 target, so it should be checked against other sources before anyone relies on it.
The article also points to further price and rating data on the platform and notes that the information is not personal investment advice.
why it matters
For the market this is a routine update to one analyst's forecast, with no clear effect on the wider sector. A higher target reflects a more optimistic view from the analyst, but on its own it does not set the direction of the stock. The mismatch between the closing price and the implied downside is worth resolving before using these numbers.
tags
instruments
sources
- HC Wainwright & Co. maintains Alpha Tau Medical at Buy, raises price target to $18 from $16 — TradingView, 20 November 2026 at 17:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗